<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25994">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02768363</url>
  </required_header>
  <id_info>
    <org_study_id>PrTK04</org_study_id>
    <nct_id>NCT02768363</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of ProstAtak® Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)</brief_title>
  <official_title>A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advantagene, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advantagene, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in
      patients undergoing active surveillance for localized prostate cancer. ProstAtak® involves
      the use of aglatimagene besadenovec (AdV-tk) to kill tumor cells and stimulate a cancer
      vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's
      immune system to detect and destroy cancer cells. ProstAtak® has been well tolerated in
      previous trials in patients with prostate cancer and other tumor types. Biochemical,
      pathologic and immune responses have been demonstrated in newly diagnosed and recurrent
      prostate cancer. The hypothesis is that ProstAtak can lead to improvement in the clinical
      outcome for patients with prostate cancer. Participants will be randomized to the ProstAtak®
      or control arm at a 2:1 ratio. Both arms receive standard of care active surveillance
      evaluations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proactive surveillance score</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical response (change in PSA)</measure>
    <time_frame>Assessed at each visit at 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Health Related Quality of Life</measure>
    <time_frame>Assessed at each visit at 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to radical treatment</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The safety profile will be characterized by collection of adverse event information and laboratory values during the treatment phase.</measure>
    <time_frame>Assessed at each visit at 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ProstAtak®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the ProstAtak arm will receive two courses of aglatimagene besadenovec + valacyclovir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to the placebo arm will receive two corresponding courses of placebo + valacyclovir</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aglatimagene besadenovec</intervention_name>
    <description>Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.</description>
    <arm_group_label>ProstAtak®</arm_group_label>
    <other_name>AdV-tk</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second placebo injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valacyclovir</intervention_name>
    <description>Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.</description>
    <arm_group_label>ProstAtak®</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:

          -  Histologically confirmed adenocarcinoma of the prostate

          -  Patients choosing active surveillance

          -  Patients meeting definition of NCCN low risk, intermediate risk OR patients having
             only one NCCN high-risk feature

               -  NCCN Low Risk is defined as having all of the following: PSA &lt; 10 ng/ml, Gleason
                  ≤ 6, T1-T2a

               -  NCCN Intermediate Risk is defined as having at least one of the following and no
                  high risk features: PSA 10-20 ng/ml, Gleason score =7, T2b-T2c

               -  High Risk with a single high risk feature is defined as having only one of the
                  following: PSA&gt;20 ng/ml, Gleason score 8-10, or T3a

               -  Excluded are those in the following risk groups: High risk with more than 1 high
                  risk factor; Locally advanced/very high risk=T3b-T4; Metastatic: N1 or M1

          -  Patients must be planning and medically able to tolerate multiple transrectal
             ultrasound guided injections.

          -  ECOG Performance status 0-2

        Exclusion Criteria include:

          -  Active liver disease, including known cirrhosis or active hepatitis

          -  Patients on systemic corticosteroids (&gt;10 mg prednisone per day) or other
             immunosuppressive drugs

          -  Known HIV+ patients

          -  Regional lymph node involvement or distant metastases

          -  Other current malignancy (except squamous or basal cell skin cancers)

          -  Other serious co-morbid illness or compromised organ function that, in the opinion of
             the investigator, would interfere with treatment or follow up

          -  Prior treatment for prostate cancer except TURP. If prior TURP, patients must be
             deemed able to receive prostate biopsy and multiple intra-prostatic injections by the
             investigator

          -  Patients taking 5-alpha-reductase inhibitors (e.g. finasteride, dutasteride)

          -  Patients who had or plan to use ADT or have history of an orchiectomy.

          -  Patients who are planning to undergo radical treatment for prostate cancer within 12
             months.

          -  Known sensitivity or allergic reactions to acyclovir or valacyclovir
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judith A Travis, BSN, RN</last_name>
      <phone>301-319-2927</phone>
      <email>judith.a.travis.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Inger L Rosner, MD, MC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margaret R Humphries, RN, CCRC</last_name>
      <phone>508-856-5711</phone>
      <email>Margaret.Humphries@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Mitchell H Sokoloff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York (Integrated Medical Professionals)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Hoffman</last_name>
      <phone>631-963-7700</phone>
      <phone_ext>205</phone_ext>
      <email>khoffman@imppllc.com</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Primiano</last_name>
      <phone>516-394-9600</phone>
      <email>mprimiano@imppllc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shawn H Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donald Bronn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York (Integrated Medical Professionals)</name>
      <address>
        <city>Hartsdale</city>
        <state>New York</state>
        <zip>10530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Hoffman</last_name>
      <phone>631-963-7700</phone>
      <phone_ext>205</phone_ext>
      <email>khoffman@imppllc.com</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Primiano</last_name>
      <phone>516-394-9600</phone>
      <email>mprimiano@imppllc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shawn H Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gurmukh Sadarangani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York (Integrated Medical Professionals)</name>
      <address>
        <city>Hauppauge</city>
        <state>New York</state>
        <zip>11749</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Hoffman</last_name>
      <phone>631-963-7700</phone>
      <phone_ext>205</phone_ext>
      <email>khoffman@imppllc.com</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Primiano</last_name>
      <phone>516-394-9600</phone>
      <email>mprimiano@imppllc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shawn H Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jigna Jhaveri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York (Integrated Medical Professionals)</name>
      <address>
        <city>North Hills</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Hoffman</last_name>
      <phone>631-963-7700</phone>
      <phone_ext>205</phone_ext>
      <email>khoffman@imppllc.com</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Primiano</last_name>
      <phone>516-394-9600</phone>
      <email>mprimiano@imppllc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shawn H Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Pearlman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York (Integrated Medical Professionals)</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <zip>11803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Hoffman</last_name>
      <phone>631-963-7700</phone>
      <phone_ext>205</phone_ext>
      <email>khoffman@imppllc.com</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Primiano</last_name>
      <phone>516-394-9600</phone>
      <email>mprimiano@imppllc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shawn H Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward Obedian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York (Integrated Medical Professionals)</name>
      <address>
        <city>West Nyack</city>
        <state>New York</state>
        <zip>10994</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Hoffman</last_name>
      <phone>631-963-7700</phone>
      <phone_ext>205</phone_ext>
      <email>khoffman@imppllc.com</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Primiano</last_name>
      <phone>516-394-9600</phone>
      <email>mprimiano@imppllc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shawn H Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arvin Adler, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Woodland Center</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maegan Elliott</last_name>
      <phone>281-351-5174</phone>
      <email>Maegan.elliott@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Chase Authement</last_name>
      <phone>281-351-5174</phone>
      <email>Chase.authement@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Steven W Sukin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Urology Specialists</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maegan Elliott</last_name>
      <phone>281-351-5174</phone>
      <email>Maegan.elliott@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Chase Authement</last_name>
      <phone>281-351-5174</phone>
      <email>Chase.authement@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Steven W Sukin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutrición, Salvador Subirán</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Feria, MD</last_name>
      <phone>+52 (55) 5487 0900</phone>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 15, 2017</lastchanged_date>
  <firstreceived_date>May 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Tumor vaccine</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>Cytotoxicity</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Active Surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
